Ani Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook

MT Newswires Live

01-13

ANI Pharmaceuticals (ANIP) said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.

ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.

Shares of the company were down 2% in recent Monday trading.

Price: 53.92, Change: -1.12, Percent Change: -2.03

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503583428"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503583428\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503583428?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503583428","market":"fut","top_or_hot":-1,"title":"Ani Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook","media":"MT Newswires Live","content":"<html><body><p> ANI Pharmaceuticals (ANIP) said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.</p><p>ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.</p><p>Shares of the company were down 2% in recent Monday trading.</p><p>Price: 53.92, Change: -1.12, Percent Change: -2.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ani Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAni Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-13 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> ANI Pharmaceuticals (ANIP) said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.</p><p>ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.</p><p>Shares of the company were down 2% in recent Monday trading.</p><p>Price: 53.92, Change: -1.12, Percent Change: -2.03</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503583428","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503583428","pubTimestamp":1736779717,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ANI Pharmaceuticals  said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.Shares of the company were down 2% in recent Monday trading.Price: 53.92, Change: -1.12, Percent Change: -2.03","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"Ani Pharmaceuticals预计2024财年调整后每股收益、收入将达到或高于指引；设定2025财年收入展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":0.9},"content_text":"ANI Pharmaceuticals (ANIP) said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.Shares of the company were down 2% in recent Monday trading.Price: 53.92, Change: -1.12, Percent Change: -2.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}